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REVIEW
Abstract: Treatment in glaucoma aims to lower intraocular pressure (IOP) to reduce the risk
of progression and vision loss. The alpha2-adrenergic receptor agonist brimonidine effectively
lowers IOP and is useful as monotherapy, adjunctive therapy, and replacement therapy in
open-angle glaucoma and ocular hypertension. A fixed combination of brimonidine and timolol,
available in some countries, reduces IOP as effectively as concomitant therapy with brimonidine
and timolol and offers the convenience of 2 drugs in a single eyedrop. Brimonidine is safe
and well tolerated. Its most common side-effects are conjunctival hyperemia, allergic
conjunctivitis, and ocular pruritus. The newest formulation of brimonidine, brimonidine-Purite
0.1%, has a higher pH to improve the ocular bioavailability of brimonidine. This formulation
contains the lowest effective concentration of brimonidine and is preserved with Purite® to
enhance ocular tolerability. Brimonidine-Purite 0.1% is as effective in reducing IOP as the
original brimonidine 0.2% solution preserved with benzalkonium chloride. Recent results
from preclinical and clinical studies suggest that brimonidine may protect retinal ganglion
cells and their projections from damage and death independently of its effects on IOP. The
potential for neuroprotection with brimonidine is an added benefit of its use in glaucoma and
ocular hypertension.
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Introduction
Glaucoma is an optic neuropathy characterized by acquired loss of retinal ganglion
cells (RGCs) and atrophy of the optic nerve leading to vision loss. Elevated intraocular
pressure (IOP) is a primary risk factor both for the development of glaucoma and for
progression of optic nerve changes and visual field loss in the disease. Abundant
evidence indicates that elevated IOP can cause the neuropathology of glaucoma.
Clinical experience with angle-closure glaucoma and numerous preclinical studies
in rats and primates have shown that acute and sustained increases in IOP can cause
optic nerve damage (Morrison 2005; Rasmussen and Kaufman 2005). Primary open-
angle glaucoma (POAG), the most common type of glaucoma in white populations,
is characterized by chronically elevated IOP with no known cause for the elevated
IOP or optic neuropathy. But many individuals with elevated IOP do not show signs
of glaucomatous optic nerve damage, and conversely, many individuals with IOP
consistently within the normal range (less than 21 mmHg) have glaucoma (Klein et
al 1992). These findings suggest that factors beyond IOP have a role in the etiology
of the disease (Drance 1997).
IOP-lowering treatment
Regardless of the etiology of the disease, at present, the aim of treatment in glaucoma
is to reduce IOP. Recent randomized, controlled clinical trials have shown that
lowering IOP is effective in delaying or preventing the development of glaucoma in
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patients with ocular hypertension (OHT) and in delaying or
halting the progression of established glaucoma (Heijl et al
2002; Kass et al 2002). IOP reduction is beneficial in
reducing the risk of progression of vision loss even when
IOP is already within the normal range (Collaborative
Normal-Tension Glaucoma Study Group 1998). Evidence
suggests that very low IOP provides the best visual outcomes
for patients (The AGIS Investigators 2000; Lichter et al
2001). Analysis of data from the Early Manifest Glaucoma
Trial showed a 10% reduction in the risk of progression
associated with each 1 mmHg of IOP reduction (Leske et al
2003).
IOP-lowering drugs are currently the only medical
treatment approved for glaucoma management. The classes
of ocular hypotensive drugs commonly used to reduce IOP
in glaucoma and OHT include prostaglandin analogues,
beta-adrenergic receptor antagonists, alpha-adrenergic
receptor agonists, carbonic anhydrase inhibitors, and
parasympathomimetics. The once-daily prostaglandin
analogues (bimatoprost, latanoprost, travoprost) reduce IOP
most effectively (Hedman and Alm 2000; Netland et al 2001;
Higginbotham et al 2002) and are often used as initial
monotherapy. Not all patients can use prostaglandin
analogues, however. Further, for many patients the IOP
lowering obtained with monotherapy is inadequate. Even
patients with OHT or early glaucoma are likely to need more
than 1 medication to reach sufficiently low pressures. For
example, in the Ocular Hypertension Treatment Study
(OHTS) by year 5 almost 40% of patients needed 2 or more
medications to achieve their target IOP (Kass et al 2002),
and in the Collaborative Initial Glaucoma Treatment Study
(CIGTS) after year 2 more than 75% of patients needed 2
or more medications to reach their target IOP (Lichter et al
2001).
Brimonidine, the only selective alpha-adrenergic
receptor agonist approved for chronic treatment in
glaucoma, is indicated for reducing IOP in patients with
open-angle glaucoma or OHT. Brimonidine is
contraindicated in patients receiving monoamine oxidase
inhibitor therapy, because antidepressants decrease the
metabolism of circulating monoamines, leading to an
increase in levels of endogenous monoamines that might
inhibit the IOP-lowering effect of brimonidine. Brimonidine
is also contraindicated in patients with hypersensitivity to
any component of the medication, and it should not be used
in children under the age of 2 because there have been
reports of apnea, bradycardia, hypothermia, hypotonia,
lethargy, and unresponsiveness in infants receiving
brimonidine treatment (Berlin et al 2001; Prok and Hall
2003).
Pharmacology and mechanism of
action of brimonidine
Brimonidine is a selective alpha2-adrenergic receptor
agonist that shows up to 1780-fold selectivity for alpha2-
over alpha1-adrenergic receptors (Cantor 2000). After
topical instillation, brimonidine reduces IOP within 1 hour,
and the peak effect occurs at 2–3 hours after dosing (Walters
1996). The trough effect occurs at 10–14 hours after dosing.
Brimonidine is usually dosed twice daily, and no additional
IOP lowering is provided at morning trough with tid versus
bid dosing (Walters 1996). Brimonidine has a dual
mechanism of IOP lowering: it both reduces aqueous
humor production and stimulates aqueous humor outflow
through the uveoscleral pathway (Toris et al 1995). The
predominant effect of short-term brimonidine treatment
is inhibition of aqueous production, whereas the
predominant effect of chronic treatment is stimulation of
aqueous humor outflow through the uveoscleral pathway
(Toris et al 1999).
Pharmacokinetics of topical
brimonidine
Pharmacokinetic studies in rabbits and monkeys have shown
that topical brimonidine readily penetrates the eye and
reaches pharmacologically active concentrations in the
aqueous humor and ciliary body, the putative sites of its
IOP-lowering activity (Acheampong et al 1995, 2002). The
primary absorption route for brimonidine is via the cornea
(Cantor 2000). Brimonidine that reaches the systemic
circulation after topical administration in humans is rapidly
metabolized and has a short plasma half-life of
approximately 2 hours (Cantor 2000). The rapid metabolism
and systemic clearance of brimonidine minimizes potential
systemic effects of the drug, and twice- or thrice-daily dosing
of brimonidine 0.2% is not associated with clinically
significant cardiovascular or pulmonary systemic effects in
adults (Cantor 2000).
Pharmacologically active concentrations of brimonidine
are found in vitreous humor samples following topical
administration of brimonidine 0.2% in rats, rabbits,
monkeys, and humans (Kent et al 2001; Acheampong et al
2002). This is important because brimonidine may be present
at the retina in concentrations sufficient for direct effects
on RGCs.Therapeutics and Clinical Risk Management 2006:2(4) 339
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Potential for neuroprotection
As it has become recognized that glaucoma is a
multifactorial, progressive neuropathy that often occurs
independently of elevated IOP, the diagnosis of glaucoma
has changed from one based on IOP to one based on the
optic nerve and visual field (Weinreb and Levin 1999). This
paradigm shift has prompted investigation of a new approach
to therapy in glaucoma called neuroprotection. The goal of
neuroprotection is to slow or prevent death of neurons and
maintain their physiological function (Weinreb and Levin
1999). One important advantage of a neuroprotective
strategy is that treatment is possible even when the etiology
of the disease is unknown or differs among patients (Weinreb
and Levin 1999). A neuroprotective treatment in glaucoma
might have no effect on IOP, but it would promote the
survival of RGCs and their axons (the optic nerve fibers),
and it could be effective regardless of the specific etiology
of the disease (Weinreb and Levin 1999).
Neuroprotection has been investigated as a therapeutic
approach for neurodegenerative conditions including stroke,
spinal cord injury, Parkinson’s disease, Huntington’s disease,
amyotrophic lateral sclerosis, and Alzheimer’s disease. It
may be difficult to achieve neuroprotection in acute
conditions such as stroke, because treatment would probably
have to begin at the time of the insult or soon after to prevent
irreversible neuronal loss (Osborne et al 2004), but
neuroprotection may be easier to achieve in chronic diseases
characterized by progressive cell loss, such as open-angle
glaucoma.
Preclinical studies have shown that brimonidine has
neuroprotective effects in animal models of optic nerve
injury relevant to glaucoma including partial optic nerve
crush, chronic ocular hypertension induced by laser cautery
of episcleral and limbal veins, and retinal ischemia induced
either by transient elevation of IOP or ligature of ophthalmic
vessels (Yoles et al 1999; Donello et al 2001; WoldeMussie
et al 2001; Mayor-Torroglosa et al 2005). Brimonidine was
shown to promote RGC survival in each of these models,
and in most studies protection of visual function was also
demonstrated through measurements of the compound
action potential or the ERG b-wave. The effects of
brimonidine are evident after topical administration of a
0.1% or 0.5% solution of drug (Vidal-Sanz et al 2001) and
are mediated by activation of alpha2-adrenergic receptors
(Donello et al 2001). Moreover, the effects appear to be
independent of IOP lowering, because systemic
administration of brimonidine, which does not reduce IOP,
is also neuroprotective (Yoles et al 1999). Recent clinical
studies of brimonidine, discussed later in this review, have
suggested that topical brimonidine treatment may also
protect RGCs in human glaucoma.
Brimonidine formulations
The original brimonidine 0.2% formulation (Alphagan
®,
Allergan, Inc, Irvine, CA, USA) has a pH of 6.4 and is
preserved with benzalkonium chloride (BAK). BAK is the
antimicrobial preservative most commonly used in
ophthalmic solutions, but chronic exposure to solutions
containing high concentrations of BAK has been associated
with harmful effects on the corneal surface (Noecker 2001;
Noecker et al 2004). Moreover, chronic treatment of
glaucoma and OHT patients with IOP-lowering ophthalmic
solutions preserved with BAK has been reported to result
in subclinical inflammation evident by increased expression
of HLA-DR on conjunctival epithelial cells (Cvenkel and
Ihan 2002). This is a clinical concern, because chronic
inflammation and fibrosis can decrease the success rate of
trabeculectomy surgery (Skuta and Parrish 1987).
Brimonidine has been reformulated to improve its
tolerability while maintaining its ocular bioavailability and
IOP-lowering efficacy. The newer formulations of
brimonidine are preserved with Purite
®, a stabilized
oxychloro complex and oxidative preservative that is
converted to natural tear components (sodium and chloride
ions, oxygen, and water) when exposed to light (Katz 2002).
Purite is a microbicide and is non-toxic to mammalian cells
(Grant et al 1996). The first reformulation of brimonidine
that was introduced contains brimonidine 0.15% in a
buffered solution of pH 7.2 preserved with Purite 0.005%
(Alphagan
® P 0.15%, Allergan Inc, Irvine, CA, USA).
Although this formulation has a reduced concentration of
brimonidine, it was shown in clinical trials to have the same
IOP-lowering efficacy and better tolerability compared with
the original brimonidine 0.2% formulation (Katz 2002)
because the increase in pH provided better bioavailability
(Dong et al 2004). More recently, a 0.1% formulation of
brimonidine preserved with Purite at a pH of 7.7 was
introduced (Alphagan
® P 0.1%, Allergan Inc, Irvine, CA,
USA). As discussed in detail below, the new brimonidine-
Purite 0.1% formulation also shows efficacy equivalent to
the original brimonidine 0.2% formulation. Animal studies
have shown that aqueous humor levels of drug are the same
with the newer formulations preserved with Purite and the
old formulation preserved with BAK, despite the lower
concentration of drug in the bottle, because at higher pH
more brimonidine is non-ionized, and brimonidine is moreTherapeutics and Clinical Risk Management 2006:2(4) 340
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readily absorbed into the eye (Dong 2004; Allergan, data
on file).
Clinical efficacy of brimonidine in
reducing IOP
In its 1-year pivotal trials for drug approval, twice-daily
brimonidine 0.2% reduced IOP as well as or better than
timolol at peak effect (2 hours after dosing) but less
effectively than timolol at morning trough (Schuman et al
1997; LeBlanc 1998; Katz 1999). The efficacy of
brimonidine was sustained over long-term use, and after
four years of treatment, brimonidine and timolol provided
comparable IOP lowering at both peak and trough effect
(David 2001). Brimonidine was well tolerated in the pivotal
trials. Common side-effects of treatment included oral
dryness, ocular hyperemia, and ocular allergy. The 1-year
incidence of treatment-related ocular allergy to brimonidine
was 11.5% (Katz 1999), but this incidence may have been
overestimated because of the confusion of dry eye, seasonal
allergic conjunctivitis, or bacterial conjunctivitis with drug-
related ocular allergy (Melamed and David 2000).
Brimonidine has been compared with dorzolamide as
monotherapy in glaucoma and OHT in 3 separate
randomized, double-masked studies with a crossover design
(Stewart et al 2000; Sharpe et al 2004; Whitson et al 2004).
In each of these studies, brimonidine and dorzolamide
showed comparable efficacy at trough effect, but at peak
effect at 2 hours after dosing, brimonidine reduced IOP by
0.7–1.4 mmHg more than dorzolamide. There was no overall
difference between drugs in the frequency of side-effects,
but ocular stinging and burning were more often associated
with dorzolamide treatment.
The versatility of brimonidine in reducing IOP was
demonstrated in a large, open-label study involving 2335
patients. In this study, brimonidine effectively reduced IOP
whether used as monotherapy, replacement therapy, or
adjunctive therapy (Lee et al 2000). As adjunctive therapy,
brimonidine provided significant mean additional IOP
lowering when added to other ocular hypotensive
medications including beta-blockers, carbonic anhydrase
inhibitors, and the prostaglandin analogue latanoprost (Lee
and Gornbein 2001). Several randomized controlled clinical
studies in patients with glaucoma or OHT subsequently
confirmed that brimonidine provides significant additional
mean decreases in IOP when added to ongoing beta-blocker
therapy (Simmons 2001; Simmons and Earl 2002; Sall et al
2003; Solish et al 2004). Other randomized controlled trials
showed that brimonidine effectively reduces IOP when used
adjunctively with a prostaglandin analogue (bimatoprost or
latanoprost) (Netland et al 2003; Zabriskie and Netland
2003; Konstas et al 2005).
Brimonidine has been demonstrated to be more effective
than dorzolamide when used as adjunctive therapy with a
beta-blocker and at least as effective as dorzolamide when
used as adjunctive therapy with latanoprost. In 2 randomized
controlled trials that compared the efficacy and safety of
brimonidine and dorzolamide as adjunctive therapy with
beta-blockers, the reduction from baseline IOP (measured
at peak effect) was significantly greater with adjunctive
brimonidine than with adjunctive dorzolamide (Simmons
2001; Carrasco Font et al 2004). Brimonidine-Purite 0.15%
was compared with dorzolamide as adjunctive therapy with
latanoprost in a randomized, double-masked, crossover trial
in 33 glaucoma patients who had uncontrolled IOP after at
least a 3-week run-in on latanoprost monotherapy (Konstas
et al 2005). Each study drug was given twice daily as
adjunctive therapy with latanoprost for 6 weeks, with a 6-
week washout between treatment periods. The primary
outcome measure was circadian IOP, measured at 7
timepoints over 24 hours after 6 weeks of adjunctive therapy.
The between-group differences in mean IOP reduction from
baseline were not statistically significant. Of the 31 enrolled
patients who had data available for analysis, 1 (3.2%) had
the same circadian IOP (average of all 7 measurements) on
both drugs, 19 (61.3%) had lower circadian IOP with
brimonidine-Purite, and 11 (35.5%) had lower circadian IOP
with dorzolamide, suggesting that brimonidine-Purite 0.15%
is at least as effective as dorzolamide in providing 24-hour
IOP control when added to latanoprost.
Clinical comparison of
brimonidine-Purite 0.1% and
brimonidine 0.2%
A prospective, randomized, double-masked, parallel-group
clinical trial compared brimonidine-Purite 0.1% with
brimonidine 0.2% for IOP-lowering efficacy and tolerability
in patients with glaucoma or OHT (Allergan, data on file).
The study was carried out at 27 centers across the United
States. Patients with glaucoma or OHT in each eye were
randomized to treatment with either brimonidine-Purite
0.1% (n=215) or brimonidine 0.2% (n=218) thrice daily for
12 months. Follow-up visits were scheduled at weeks 2 and
6 and months 3, 6, 9, and 12. IOP was measured at 8 AM
(trough effect, immediately prior to the morning dose), 10
AM (morning peak effect), and 4 PM (afternoon peak effect,Therapeutics and Clinical Risk Management 2006:2(4) 341
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2 hours after the afternoon dose) at all follow-up study
visits except month 9, when it was measured at 8 AM
and 10 AM only. The primary efficacy measure was mean
IOP in the intent-to-treat patient population (all
randomized patients) with last observation carried
forward for missing values. All patients were treated
bilaterally, and the average IOP from both eyes was used
in the analyses.
Baseline demographic and ophthalmic characteristics of
patients were similar between the 2 treatment groups. Mean
IOP at baseline was also comparable between the 2 treatment
groups at each hour. Throughout follow-up, mean IOP in
each treatment group ranged from 17 to 22 mmHg and was
significantly lower than at baseline (p <0.001). The absolute
values of the limits of the 95% confidence interval (CI) of
the between-group difference in mean IOP were <1.0 mmHg
at 12 of 17 timepoints and <1.5 mmHg at all 17 timepoints,
demonstrating equivalent efficacy of the study formulations
(Figure 1). Analysis of mean change from baseline IOP also
showed equivalent efficacy of the study formulations, with
the absolute values of the limits of the 95% CI of the
between-group difference <1.0 mmHg at 9 of 17 timepoints
and consistently <1.5 mmHg. The only significant
differences in mean IOP reduction between treatment groups
were at 4 PM at months 3 and 12, when the mean IOP
reduction was significantly greater with brimonidine-Purite
0.1% than with brimonidine 0.2% (p ≤0.043). Brimonidine-
Purite 0.1% provided sustained IOP lowering over 12
months of treatment and was as effective as brimonidine
0.2% in reducing IOP at all timepoints. Figure 2 shows the
mean change from baseline IOP with each formulation at
the 10 AM timepoint of peak effect.
The percentage of patients with 1 or more treatment-
related adverse events was lower in the brimonidine-Purite
0.1% group (41.4%) than in the brimonidine 0.2% group
(53.2%, p=0.014). The only individual treatment-related
adverse event with a significant difference in incidence
between treatment groups was oral dryness, which was less
frequent in the brimonidine-Purite 0.1% group (1.4% of
patients) than in the brimonidine 0.2% group (5.5% of
patients, p=0.019). Biomicroscopic findings of increased
severity of lid erythema and lid edema were also less
common in the brimonidine-Purite 0.1% group (p=0.028
and p=0.006, respectively).
The rate of discontinuations for adverse events was
significantly lower in the brimonidine-Purite 0.1% group
(21.4%) than in the brimonidine 0.2% group (33.5%,
p=0.005). Only 1 patient in the brimonidine-Purite 0.1%
group discontinued for a non-ocular, treatment-related
adverse event (oral dryness). In contrast, patients in the
brimonidine 0.2% group discontinued for several non-ocular
treatment-related adverse events including asthenia,
hypotension, somnolence, depression, and insomnia, as well
as oral dryness.
In summary, the results of this trial showed that
brimonidine-Purite 0.1% is statistically equivalent to
Figure 1 Equivalent IOP-lowering efficacy of brimonidine-Purite 0.1% and brimonidine 0.2%. In a 1-year clinical comparison study of the 2 formulations, the 95% CI
of the difference in mean IOP between treatment groups (brimonidine-Purite 0.1% minus brimonidine 0.2%) was consistently within the range of –1.5 mmHg to
1.5 mmHg, demonstrating equivalent efficacy of the study formulations.
Abbreviations: CI, confidence interval; IOP, intraocular pressure.
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brimonidine 0.2% in IOP-lowering efficacy and at least as
well tolerated in patients with glaucoma and OHT.
Safety and tolerability
Brimonidine has a favorable safety and tolerability profile.
Unlike the beta-adrenergic antagonists, there are no
cardiopulmonary contraindications to its use, and
brimonidine can be safely and effectively used by patients
on systemic anti-hypertensive beta-blocker therapy
(Schuman 2000). In contrast to the prostaglandin analogues,
brimonidine has not been associated with eyelash growth
or increased pigmentation of the iris or eyelids. The side-
effects associated with brimonidine treatment are usually
ocular and include conjunctival hyperemia, allergic
conjunctivitis, and ocular pruritus. The most common
systemic side-effects are oral dryness and fatigue or
drowsiness.
The reduced drug concentration in the brimonidine-
Purite 0.15% formulation compared with brimonidine 0.2%
led to an improvement in tolerability (Katz 2002). In a
randomized, double-masked, comparison trial of these
formulations, glaucoma and OHT patients treated with the
brimonidine-Purite 0.15% formulation had a 41% lower
incidence of allergic conjunctivitis (Katz 2002). Oral
dryness, conjunctival hyperemia, and eye discharge were
also significantly less common with brimonidine-Purite
0.15% than with brimonidine 0.2% (Katz 2002).
The brimonidine–Purite 0.1% formulation also has a
favorable safety and tolerability profile. Because the active
drug concentration is 33% less than in the brimonidine-
Purite 0.15% formulation, the ocular surface is exposed to
less drug, and systemic absorption of brimonidine through
the nasolacrimal pathway is likely to be further reduced with
the 0.1% formulation. Consistent with this suggestion, in a
study in rabbits, aqueous humor levels of drug were similar
after dosing with either the brimonidine-Purite 0.15% or
0.1% formulation, but plasma levels of brimonidine were
lower in animals dosed with the brimonidine-Purite 0.1%
formulation (Allergan, data on file). These results suggest
the possibility that the new brimonidine-Purite 0.1%
formulation may have an improved systemic safety profile
over brimonidine-Purite 0.15%, but clinical comparison
studies will be needed to confirm this possibility.
Patient acceptance and
compliance with brimonidine
treatment
Brimonidine treatment is usually well received by patients.
In the phase 3 clinical comparison of brimonidine-Purite
0.15% and brimonidine 0.2%, most patients (approximately
80%) considered their eyedrops to be comfortable and were
satisfied with their treatment (Katz 2002). Patient comfort
ratings and satisfaction ratings were significantly higher with
the brimonidine-Purite 0.15% formulation than with
brimonidine 0.2%.
It is generally recognized that lack of compliance with
medical treatment is a significant problem in many diseases,
and compliance may be particularly poor in slowly
progressive, largely asymptomatic chronic diseases such as
glaucoma. Poor compliance can lead to treatment failure,
yet up to 80% of glaucoma patients may not take their
medication as prescribed (Olthoff et al 2005). The reasons
for non-compliance in glaucoma are not completely
understood, but patients often mention forgetfulness as their
main reason for not taking their eyedrops (Taylor et al 2002),
and self-reported difficulty in remembering to take glaucoma
medications has been significantly associated with patient
nonadherence to treatment (Sleath et al 2006). Other reasons
for non-compliance with medical treatment in glaucoma may
include cost of medications, inconvenience of the dosing
schedule, inability to instill the eyedrops correctly, and lack
of understanding of the need for chronic therapy (Winfield
et al 1990). Side-effects are usually not a significant cause
of noncompliance (Olthoff et al 2005; Taylor et al 2002).
Required instillation of drops at 3 or more times during the
day is strongly associated with reduced compliance (Olthoff
et al 2005), but this is generally not a concern with
brimonidine treatment, because brimonidine is usually dosed
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Figure 2 Mean change from baseline IOP. Both brimonidine-Purite 0.1% and
brimonidine 0.2% provided significant IOP reductions that were sustained
throughout 1 year of therapy. The mean IOP reduction was equivalent with the
2 formulations throughout follow-up.
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twice daily. There is currently no evidence to suggest that
compliance with brimonidine treatment is either better or
worse than treatment compliance with other classes of ocular
hypotensive medications.
Clinical trials of neuroprotection
with brimonidine
An initial trial evaluating potential neuroprotection by
brimonidine in patients with acute angle-closure glaucoma
found no difference between the number of patients who
progressed during treatment with brimonidine or timolol
(Aung et al 2004). The study was limited because overall,
only 59 patients completed the study, and only 11 of these
patients progressed during the study, but there was a trend
for the rate of progression to be lower in patients treated
with brimonidine (Aung et al 2004). A second trial evaluated
potential neuroprotection by brimonidine in patients with
non-arteritic anterior ischemic optic neuropathy (NAION)
(Wilhelm et al 2006). This was a randomized, double-
masked study that evaluated 29 patients with first eye
involvement who were treated with brimonidine 0.2% or
placebo within the first week after loss of visual acuity. After
3 months of treatment there was a trend for better visual
field results on all measures in the brimonidine group. The
study was stopped after an interim analysis, however, when
the investigators concluded that the number of patients
needed for statistical significance could not be recruited
within a practical time frame.
A randomized, double-masked, pilot study evaluated
potential neuroprotection by brimonidine in eyes of
patients undergoing laser treatment for extrafoveal or
juxtafoveal choroidal neovascularization (CNV) (Ferencz
et al 2005). Eyes were treated with brimonidine 0.2%
(study group, 11 eyes) or placebo (control group, 9 eyes)
twice daily, beginning at 4–48 hours before laser
treatment and continuing afterwards for 1 month. In each
treatment group, 2 eyes had recurrence of CNV in the
subfoveal region and severe visual loss after the
photocoagulation procedure. For the remaining 16 eyes,
mean visual acuity at 2 months after laser treatment was
improved in the brimonidine group but not in the control
group. The investigators suggested that the improvement
in visual acuity in brimonidine-treated patients most
likely resulted from an ability of brimonidine to protect
RGCs from damage induced by noxious substances
released from cells destroyed by the laser treatment
(Ferencz et al 2005).
A recent trial has provided encouraging results
suggesting neuroprotective effects of brimonidine in
glaucoma patients (Tsai and Chang 2005). In this
prospective, randomized, unmasked study, 78 patients with
newly diagnosed POAG were treated with brimonidine 0.2%
twice daily or timolol 0.5% ophthalmic gel-forming solution
once daily in the morning for 12 months. Eligible patients
were required to have untreated IOP >21 mmHg, a
glaucomatous appearance of the optic disc, and an abnormal
visual field on standard automated perimetry. IOP was
measured at 2-month intervals throughout the study. Retinal
nerve fiber layer (RNFL) thickness was measured using
scanning laser polarimetry (GDx) at baseline and at the end
of the study.
At baseline, there were no significant between-group
differences in patient age, sex, visual field mean deviation
and corrected pattern standard deviation, and IOP. Baseline
RNFL thickness measurements including the ellipse average,
superior average, temporal average, inferior average, and
nasal average were also comparable between treatment
groups. After 12 months of follow-up, patients in the timolol
group showed a significant mean decrease in all RNFL
measurements (p ≤0.044) consistent with glaucomatous
progression of RGC loss. In contrast, patients in the
brimonidine group showed no significant changes in any of
the RNFL thickness measurements (p ≥0.14) and there was
no evidence for glaucomatous loss of the RNFL. The
between-group comparison of mean change from baseline
RNFL thickness showed significantly greater loss of
temporal average (p=0.005), inferior average (p=0.016), and
ellipse average (p=0.020) RNFL thickness in the timolol
group compared with the brimonidine group.
No significant between-group differences in mean IOP
were found at baseline or at any follow-up study visit (p
≥0.038). The mean IOP reduction at the month 12 visit was
5.6 mmHg in the brimonidine group and 5.3 mmHg in the
timolol group (p=0.16). Therefore, the differences in RNFL
loss between the treatment groups are unlikely to be
explained by better IOP control in the brimonidine group.
Instead, the findings are likely to be explained by a direct
neuroprotective effect of brimonidine, which promoted the
survival of RGCs and their axons, and thereby prevented
glaucomatous damage to the RNFL. The brimonidine-Purite
0.15% and 0.1% formulations would be expected to have a
similar neuroprotective effect, if (as is likely)
neuroprotection results from brimonidine activity at the
retina, rather than from systemic effects of the drug.Therapeutics and Clinical Risk Management 2006:2(4) 344
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This latest study provides the strongest published results
to date suggesting that neuroprotection with brimonidine
may be a viable strategy for treatment in glaucoma. The use
of scanning laser polarimetry allowed quantitative
evaluation of structural changes in the RNFL and
demonstrated possible neuroprotection of RGCs by
brimonidine. Further studies that evaluate the ability of
brimonidine and other potential neuroprotective agents to
prevent the progression of functional changes and visual
field loss in glaucoma are eagerly anticipated.
Fixed combination of brimonidine
and timolol
A fixed combination of brimonidine 0.2%/timolol 0.5%
(Combigan
®, Allergan Inc, Irvine, CA, USA) is available
in some countries. The fixed combination is preserved with
BAK and contains 0.2% brimonidine and timolol 0.5%. A
3-month, randomized, double-masked, clinical study in 1159
patients with glaucoma or OHT showed that the
brimonidine/timolol fixed combination is more efficacious
than either of its component medications (Craven et al 2005).
In this study, at all follow-up timepoints the reduction from
baseline IOP was significantly greater in patients treated
with the brimonidine/timolol fixed combination BID than
in those treated with timolol BID monotherapy (p ≤0.026).
At all 8 AM, 10 AM, and 3 AM timepoints, the mean
reduction from baseline IOP was also greater for patients
treated with the fixed combination than for those treated
with brimonidine tid monotherapy (p <0.001) (Craven et al
2005). The fixed combination bid was better tolerated than
brimonidine tid monotherapy but not as well tolerated as
timolol bid monotherapy.
The brimonidine/timolol fixed combination lowers IOP
as effectively as concomitant therapy with separate drops
of brimonidine 0.2% and timolol 0.5% (Gõni 2005). In a
randomized, double-masked, clinical trial, 371 glaucoma
or OHT patients with inadequate IOP control after at least 3
weeks of run-in monotherapy were switched to either the
fixed combination of brimonidine/timolol bid or
concomitant timolol bid and brimonidine bid therapy (Gõni
2005). Both treatments provided significant additional IOP
lowering from baseline on monotherapy. Differences
between the fixed combination and concomitant therapy
were ≤0.35 mmHg for mean IOP and ≤0.30 mmHg for mean
change from baseline IOP at all timepoints over the 3-month
study, and none of the differences were statistically
significant. No differences in tolerability were noted
between the fixed combination and concomitant therapy.
Use of the fixed combination rather than separate drops of
brimonidine and timolol does, however, reduce corneal
exposure to BAK, and this may help reduce corneal toxicity
associated with chronic treatment (Gõni 2005). Dosing of
the fixed combination is also easier and more convenient,
because there is no need to wait between instillation of
separate drops. It was suggested that this increase in
convenience may result in better patient compliance and a
higher rate of treatment success (Choudhri et al 2000).
Place of brimonidine in therapy for
glaucoma and OHT
Brimonidine can be used as monotherapy in glaucoma and
OHT, but it is more commonly used as adjunctive therapy.
The once-daily prostaglandin analogue drugs are generally
the preferred choice for first-line therapy because they
provide the lowest IOP and consistent IOP control
throughout the day. Beta-blockers are also considered an
appropriate choice of first-line therapy for some patients.
Regardless of the first-line therapy, most patients eventually
require more than 1 ocular hypotensive medication for
adequate IOP control, and brimonidine is considered a
preferred choice for adjunctive therapy because of its
effectiveness in adjunctive therapy with multiple classes of
IOP-lowering medications and its favorable safety and
tolerability profile (Lee and Higginbotham 2005). There is
particularly strong evidence that brimonidine is effective
when used in combination with a beta-blocker, either when
given as a separate drop or in the brimonidine/timolol fixed
combination. For patients whose treatment regimen includes
both brimonidine and timolol, use of the fixed combination
may be preferred because fixed-combination treatment
offers potential advantages of increased compliance, reduced
costs, and reduced cumulative exposure to BAK (Fechtner
and Realini 2004).
The brimonidine-Purite 0.15% formulation is clearly
preferable to the brimonidine 0.2% formulation because it
provides the same efficacy and better tolerability. The
brimonidine-Purite 0.1% formulation also provides the same
efficacy as brimonidine 0.2%, and the reduced drug exposure
associated with its use is likely to result in improved long-
term safety and tolerability of treatment. Because
brimonidine-Purite 0.15% and the new brimonidine-Purite
0.1% are formulated at a different pH, however, comparative
clinical studies will be needed to determine their
comparative efficacy and safety.Therapeutics and Clinical Risk Management 2006:2(4) 345
Brimonidine therapy in glaucoma and ocular hypertension
Results of the clinical trials of neuroprotection with
brimonidine are promising, and it now seems reasonable to
consider the potential for neuroprotection when choosing
therapy for glaucoma. Brimonidine can be used safely and
reliably to reduce IOP in glaucoma and OHT, and it may
also reduce the risk of glaucomatous progression
independent of its effects on IOP.
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